What are the targets of teritolumab? Which cells or pathological mechanisms does it primarily target?

Teclistamab is an innovative immunotherapy drug that belongs to the class of bispecific antibody drugs. Its mechanism of action is to enhance the body's immune system's ability to recognize and eliminate tumor cells through dual targeting. The main targets of teritusumab include B cell immunoglobulin-like receptor (BCMA) and CD3.

BCMA is a protein mainly expressed on plasma cells and certain B cell subsets. It plays an important role in the occurrence and progression of hematological tumors such as multiple myeloma. BCMA is highly expressed on the surface of tumor cells in patients with multiple myeloma, making it a key target for teritusumab. Teritusumab binds to BCMA, allowing the immune system to recognize and attack these tumor cells, thereby effectively inhibiting tumor growth.

CD3 is an important receptor on the surface of T cells and is a core component of T cell immune responses. The other end of teritusumab specifically binds to the CD3 receptor, prompting T cells to contact BCMA-expressing tumor cells. When teritolumab connects T cells and tumor cells, the T cells are activated and release cytotoxic substances (such as cytokines and enzymes) to directly kill tumor cells. This mechanism of dual targeting BCMA and CD3 enhances the immune system's attack on tumors.
Through its bispecific effect, Teritusumab can not only accurately identify and eliminate BCMA-positive tumor cells, but also enhance immune responses by activating T cells. This mechanism gives teritusumab a clear advantage in treating diseases such as multiple myeloma. Compared with traditional single-target therapy, the dual-target design can provide stronger therapeutic efficacy and reduce the possibility of tumor cell escape.
Currently, teritusumab is mainly used to treat multiple myeloma, especially in patients with relapsed or refractory multiple myeloma that is refractory to traditional treatments. By targeting BCMA and CD3, teritusumab can significantly improve patients' treatment response rate and survival, and has shown good efficacy and safety in clinical trials. As more studies are conducted, terituximab may be expanded to other types of tumor treatment in the future to further verify its potential in tumor immunotherapy.
Reference: https://www.tecvayli.com/